01 July 2021

Polpharma invests PLN 300 million in R&D

On June 29, we signed another significant loan agreement with the European Investment Bank. The investment of PLN 300 million will finance our research, development and innovation (RDI) programme until 2023. The investment will strengthen our position by developing the portfolio of new products and will improve patients’ access to modern medicines in several therapeutic areas, including cardiology, diabetes, ophthalmic and respiratory diseases.

“Polpharma’s purpose is to help people live a healthy life in a healthy world. A key role in our activity is played by the development of modern pharmaceutical products that respond to contemporary health challenges, ensure drug security and expand access to effective therapies for patients in Poland and Europe. Cooperation with the EIB will help us effectively implement our long-term development plans and innovative patient-friendly solutions as well as create attractive jobs for the best specialists” – says Wojciech Rosa, Member of Polpharma S.A. Management Board.

The European Investment Bank (EIB) is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy objectives. EIB is supporting investments in RDI that strengthen Europe’s long-term competitiveness, promote knowledge diffusion, drive economic growth and create jobs. The Innovation Loan is subject to technical viability and quality assessment by the Bank’s Projects department, which has years of broad expertise in assessing RDI programmes across a multitude of sectors and company sizes, in the EU and worldwide.

Polpharma on its websites and mobile applications (“Website”) uses cookies and other related technologies (“cookies”). Self-management of cookies is possible by changing the settings in your web browser. If you do not agree to the collection of personal data through cookies, you can change the settings in your web browser or leave the Website.

By using the Website without changing the settings in your web browser, you accept Polpharma’s use of cookies. By accepting the settings in your web browser, you agree to profiling based on the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect the lawfulness of the processing that was carried out on the basis of consent before its withdrawal.

More information can be found in the Cookies Policy.